Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo.
about
Pseudomonas endophthalmitis associated with scleral necrosis.Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis modelVersatility of aminoglycosides and prospects for their future.In vivo antibiotic synergism: contribution of animal models.Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit modelEmpiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceCombination therapy for treatment of infections with gram-negative bacteria.Antibiotic combinations: should they be tested?Rapid diagnosis of Pseudomonas aeruginosa urinary tract infections by radioimmunoassay.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitroIn vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa.Ticarcillin bioassay.Effect of time and concentration upon interaction between gentamicin, tobramycin, Netilmicin, or amikacin and carbenicillin or ticarcillin.Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.Optimization and evaluation of piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics via the hollow-fiber infection model and mechanism-based modeling.Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.
P2860
Q33652116-B72B44DE-126D-43D2-8ABE-E756B43B709AQ35109053-2D7AE0CE-54C1-4144-A266-F92B881039E3Q35176271-49F9BAC6-4DDE-4D67-B3D8-04A532790AB5Q35754023-64CA78DB-E7A1-4D5E-862F-6BEAE4519BAFQ35759586-27C4A7B6-7F1B-43A5-9363-0EF479B5717DQ36089167-46B440C5-BE70-4931-A5E2-7E57C62ABF93Q36156077-9F6F82AD-196A-4392-8280-CC8E5932D200Q36632795-8F3B0D66-93A9-4EBE-91D1-AAA2388DEC53Q37313472-188F2C57-B56F-4FE9-8EA6-AC58FCC3DE77Q37563029-4E696833-F51B-45D6-BF16-C56459DF36FAQ39604645-B8BBCA90-CA14-4791-A79D-980072DBE1B4Q39611982-6AC8578C-6902-46B5-BCC6-9A6A58503A17Q39855881-4474DBC3-8F39-40EC-8AE2-6FB51DC22F0DQ40620360-0FF9F892-14EB-42A8-9C18-23A0D989DAFFQ46532816-7E41D289-303C-45C5-9471-E6E80BA6AE97Q47656109-6680051C-9AB0-4E59-9A5B-1995E8DB2727Q49792113-02ED551A-F1C5-4F88-BA4E-30D1F5335930Q54433712-825F9C17-35B0-492C-9E9B-488A0513D64A
P2860
Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh
1977年學術文章
@zh-hant
name
Synergy between ticarcillin an ...... eriaceae in vitro and in vivo.
@ast
Synergy between ticarcillin an ...... eriaceae in vitro and in vivo.
@en
type
label
Synergy between ticarcillin an ...... eriaceae in vitro and in vivo.
@ast
Synergy between ticarcillin an ...... eriaceae in vitro and in vivo.
@en
prefLabel
Synergy between ticarcillin an ...... eriaceae in vitro and in vivo.
@ast
Synergy between ticarcillin an ...... eriaceae in vitro and in vivo.
@en
P2093
P2860
P356
P1476
Synergy between ticarcillin an ...... eriaceae in vitro and in vivo.
@en
P2093
Osborne CD
Sutherland R
P2860
P304
P356
10.1128/AAC.11.6.956
P407
P577
1977-06-01T00:00:00Z